Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.
Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. Pardee TS, et al. Among authors: isom s. Clin Cancer Res. 2014 Oct 15;20(20):5255-64. doi: 10.1158/1078-0432.CCR-14-1019. Epub 2014 Aug 27. Clin Cancer Res. 2014. PMID: 25165100 Free PMC article. Clinical Trial.
A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.
Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL. Pardee TS, et al. Among authors: isom s. Clin Cancer Res. 2018 May 1;24(9):2060-2073. doi: 10.1158/1078-0432.CCR-17-2282. Epub 2018 Feb 6. Clin Cancer Res. 2018. PMID: 29437791 Free PMC article. Clinical Trial.
Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia.
Anderson R, Miller LD, Isom S, Chou JW, Pladna KM, Schramm NJ, Ellis LR, Howard DS, Bhave RR, Manuel M, Dralle S, Lyerly S, Powell BL, Pardee TS. Anderson R, et al. Among authors: isom s. Nat Commun. 2022 Mar 30;13(1):1673. doi: 10.1038/s41467-022-29039-4. Nat Commun. 2022. PMID: 35354808 Free PMC article. Clinical Trial.
Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW. Monjazeb AM, et al. Among authors: isom s. J Clin Oncol. 2010 Nov 1;28(31):4714-21. doi: 10.1200/JCO.2010.30.7702. Epub 2010 Sep 27. J Clin Oncol. 2010. PMID: 20876421 Free PMC article.
Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases.
Johnson AG, Ruiz J, Hughes R, Page BR, Isom S, Lucas JT, McTyre ER, Houseknecht KW, Ayala-Peacock DN, Bourland DJ, Hinson WH, Laxton AW, Tatter SB, Debinski W, Watabe K, Chan MD. Johnson AG, et al. Among authors: isom s. Oncotarget. 2015 Aug 7;6(22):18945-55. doi: 10.18632/oncotarget.4153. Oncotarget. 2015. PMID: 26087184 Free PMC article.
145 results